Monica Wallter
CEO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 737 070922
Email: monica.wallter@liddspharma.com
Anja Peters
CFO
Virdings allé 32B, Uppsala
SE-754 50, Sweden
Phone: +46 733 260000
Email: anja.peters@liddspharma.com
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Financial Calendar
Subscribe for news
Press releases
- 2020-10-26
LIDDS’ NanoZolid-TLR9 agonist demonstrates strong and durable preclinical anti-tumoral effect - 2020-10-19 LIDDS announces outcome of subscription of shares in the incentive programs 2017/2020
- 2020-09-30 LIDDS Announces Data on Liproca Depot from Open Label Extension Study
- 2020-08-20 LIDDS Delårsrapport januari – juni 2020
LIDDS företrädesemission kraftigt övertecknadLIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
